”Outline of vaccine development against SARS-CoV2 as of May 7.”
【紹介文献】
Gao et al., 2020, Science (06 May 2020)
"Rapid development of an inactivated vaccine candidate for SARS-CoV-2"
https://science.sciencemag.org/content/early/2020/05/05/science.abc1932
【発表概要】
SARS-CoV2のワクチンには，弱毒化ワクチン，不活化ワクチン，組み換えタンパク，ウイルス，DNAやmRNAが利用されている。現在までに，104個が非臨床，臨床ステージにある。その中で，開発が最も進んでいる不活化ワクチンがサルで予防効果を示した論文を紹介する(SINOVAC社)。本ワクチンは5月7日現在Ph1/2であるが，大量生産の製造に課題がある。一方，mRNAワクチンは比較的製造が容易である。
SARS-CoV-2では未だmRNAワクチンのデータは報告されていないが，mRNAワクチンの技術の一部を紹介したい。
【Summary】
Various kinds of vaccination approaches are examined against SARS-CoV2, such as attenuated vaccines, inactivated vaccines, protein-based vaccines, DNA-based vaccines and mRNA-based vaccines. To date, 104 SARS-CoV2 vaccine candidates have been evaluated in non-clinical and clinical stages. Among them, I will mainly introduce the most advanced candidate of inactivated vaccine developed by Sinovac Biotech, which showed a protective effect against SARS-CoV2 in monkeys. This vaccine is in Ph1/2 stage as of May 7, but there is a problem of mass production. On the other hand, mRNA vaccines are relatively easier to manufacture than other types of vaccines.
So I would like to introduce some topics about mRNA vaccines as well, although data on mRNA vaccines for SARS-CoV2 have not been reported yet.
発表資料
(2020.5.14 iPark Science Cafe 33th)
